OBJECTIVE: To probe into the efficacy of recombinant human interferon α1b for injection in aerosol inhalation treatment of child bronchitis .METHODS:276 child patients with bronchitis admitted into the Eighth People 's Hospital of Nanning from Sept .2015 to Jun.2016 were selected and divided into observation group (140 cases ) and control group (136 cases) via random number table .Both groups were given conventional treatment , on this basis, the control group was treated with compound ipratropium bromide aerosol , while the observation group was given recombinant human interferon α1b injection for aerosol inhalation , treated with 7 days.Clinical efficacy , disappearance time of symptoms and incidences of adverse drug reactions of two groups were observed .RESULTS:The total effective rate of observation group (99.3％, 139/140) was significantly higher than that of the control group (86.8％, 118/136), with statistically significantly difference (P0.05).CONCLUSIONS:The efficacy of recombinant human interferon α1b for injection in aerosol inhalation treatment of child bronchitis is remarkable , which can significantly relieve patients 'symptoms , with high safety .%目的:探讨注射用重组人干扰素α1 b雾化吸入治疗小儿支气管炎的疗效及安全性.方法:选取2015年9月—2016年6月南宁市第八人民医院收治的小儿支气管炎患者276例作为研究对象,以随机数字表法分为观察组140例和对照组136例.两组患儿均给予常规治疗,在此基础上,对照组患儿雾化吸入复方异丙托溴铵气雾剂,观察组患儿雾化吸入注射用重组人干扰素α1b,均连续雾化吸入7 d.观察两组患儿的临床疗效、症状消失时间和不良反应发生情况.结果:观察组患儿的总有效率为99.3％(139/140),明显高于对照组的86.8％(118/136),差异有统计学意义(P0.05).结论:注射用重组人干扰素α1b雾化吸入治疗小儿支气管炎的疗效显著,可缓解患儿症状,且安全性较高.
展开▼
